Grifols, a CataloniaBio & HealthTech member, has entered into a formal collaboration with the Food and Drug Administration (FDA) and other public health agencies of United States to collect plasma from convalescent Covid-19 patients and process it into a hyperimmune globulin.

The agreement also includes to support preclinical and clinical studies to determine the efficacy of the new therapy as a viable treatment for Covid-19 disease and as a platform for future emerging infectious diseases.

In addition, Grifols has accelerated the development and validation of a proprietary technology TMA (transcription-mediated amplification) based diagnostic procedure with a hight sensitivity. The test will be performed on automatic instrumentation, with each unit able to run more than 1,000 samples per day, and that will be ready in the following weeks.

More information

Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream